Elevated Galectin-3 levels in the tumor microenvironment of ovarian cancer - implication of ROS mediated suppression of NK cell antitumor response via tumor-associated neutrophils

Front Immunol. 2024 Dec 20:15:1506236. doi: 10.3389/fimmu.2024.1506236. eCollection 2024.

Abstract

Introduction: Ovarian cancer is a lethal disease with low survival rates for women diagnosed in advanced stages. Current cancer immunotherapies are not efficient in ovarian cancer, and there is therefore a significant need for novel treatment options. The β-galactoside-binding lectin, Galectin-3, is involved in different immune processes and has been associated with poor outcome in various cancer diagnoses. Here, we investigated how Galectin-3 affects the interaction between natural killer (NK) cells and neutrophils in the tumor microenvironment of ovarian cancer.

Method: Ascites from the metastatic tumor microenvironment and cyst fluid from the primary tumor site were collected from patients with high-grade serous carcinoma (HGSC) together with peripheral blood samples. Galectin-3 concentration was measured in ascites, cyst fluid and serum or plasma. Neutrophils isolated from HGSC ascites and autologous blood were analyzed to evaluate priming status and production of reactive oxygen species. In vitro co-culture assays with NK cells, neutrophils and K562 target cells (cancer cell line) were conducted to evaluate NK cell viability, degranulation and cytotoxicity.

Results: High levels of Galectin-3 were observed in cyst fluid and ascites from patients with HGSC. Neutrophils present in HGSC ascites showed signs of priming; however, the priming status varied greatly among the patient samples. Galectin-3 induced production of reactive oxygen species in ascites neutrophils, but only from a fraction of the patient samples, which is in line with the heterogenous priming status of the ascites neutrophils. In co-cultures with NK cells and K562 target cells, we observed that Galectin-3-induced production of reactive oxygen species in neutrophils resulted in decreased NK cell viability and lowered anti-tumor responses.

Conclusion: Taken together, our results demonstrate high levels of Galectin-3 in the tumormicroenvironment of HGSC. High levels of Galectin-3 may induce production of reactiveoxygen species in ascites neutrophils in some patients. In turn, reactive oxygen species produced by neutrophils may modulate the NK cell anti-tumor immunity. Together, this study suggests further investigation to evaluate if a Galectin-3-targeting therapy may be used in ovarian cancer.

Keywords: NK cells; ROS release; galectin-3; neutrophils; ovarian cancer; tumor immunology; tumor microenvironment.

MeSH terms

  • Aged
  • Blood Proteins
  • Cell Line, Tumor
  • Cytotoxicity, Immunologic
  • Female
  • Galectin 3* / metabolism
  • Galectins / metabolism
  • Humans
  • K562 Cells
  • Killer Cells, Natural* / immunology
  • Killer Cells, Natural* / metabolism
  • Middle Aged
  • Neutrophils* / immunology
  • Neutrophils* / metabolism
  • Ovarian Neoplasms* / immunology
  • Ovarian Neoplasms* / metabolism
  • Ovarian Neoplasms* / pathology
  • Reactive Oxygen Species* / metabolism
  • Tumor Microenvironment* / immunology

Substances

  • Reactive Oxygen Species
  • Galectin 3
  • Galectins
  • LGALS3 protein, human
  • Blood Proteins

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This project was supported by the Swedish cancer foundation (20 0226 P 01 H; EB and CAN 2018/384; KS), the Swedish research council (2019-06328; EB), the Swedish Society for Medical Research (EB), the Swedish Society for Medicine (SLS-881711; EB), the Assar Gabrielsson foundation (BRG20-06, FB23-112; EB), Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (965552; KS), Cancera and the Swedish Cancer Society (21-1848; KS), the Swedish state under the TUA-agreement (TUAGBG-916951 & TUAGBG-978190; KC), the Åke Wiberg Foundation (M21-0025 and M23-0193; MS), the Sahlgrenska International Starting Grant (GU2021/1070; MS), the King Gustaf the V 80-year foundation (FAI-2021-0804 and FAI-2022-0873; MS), the Rune and Ulla Almlövs Foundation (2023-418; MS), the Mary von Sydow foundation (4723; MS), the Magnus Bergwall foundation (2023-875; MS), the Swedish Rheumatism Association (R-995669; MS), the Wilhelm and Martina Lundgren Science Fund (2024-SA-4605; MS and 2022-4083; EB).